Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of -0.11 is 2958% below its 5-year average of 0.00, around the middle of its 5-year range (-0.43–0.04).
As of the fiscal period ended Wednesday, December 31, 2025. 187.25% below its 12-month average of -0.04.
Reported quarterly debt to equity ratio; no daily interpolation. Q4 FY2025 (2025-12-31): -0.11.
DEBT TO EQUITY RATIO
-0.11
DEBT TO EQUITY RATIO AVG TTM
-0.04
DEBT TO EQUITY RATIO AVG 3Y
-0.02
DEBT TO EQUITY RATIO AVG 5Y
0.00
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-187.25%
CURRENT VS 3Y AVG
-347.36%
CURRENT VS 5Y AVG
-2957.51%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.13
median of 579 covered companies
CURRENT VS SECTOR MEDIAN
-183.83%
vs the sector median at left
NeuroSense Therapeutics Ltd.
Market Cap
$7.22M
Debt to Equity Ratio
-0.11
TTM Avg
-0.04
3Y Avg
-0.02
5Y Avg
0.00
Market Cap
$7.13M
Debt to Equity Ratio
0.06
TTM Avg
0.01
3Y Avg
0.01
5Y Avg
0.01
Market Cap
$7.31M
Debt to Equity Ratio
0.00
TTM Avg
0.03
3Y Avg
0.05
5Y Avg
0.05
Market Cap
$7.08M
Debt to Equity Ratio
0.03
TTM Avg
0.02
3Y Avg
0.20
5Y Avg
0.20
Market Cap
$7.07M
Debt to Equity Ratio
0.14
TTM Avg
0.05
3Y Avg
0.03
5Y Avg
0.02
Market Cap
$6.67M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| NeuroSense Therapeutics Ltd. (NRSN) | $7.22M | -0.11 | -0.04 | -0.02 | 0.00 |
| KALA BIO, Inc. (KALA)vs › | $7.28M | 0.00 | 1.31 | 2.43 | 2.58 |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $7.13M | 0.06 | 0.01 | 0.01 | 0.01 |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.31M | 0.00 | 0.03 | 0.05 | 0.05 |
| Mangoceuticals, Inc. (MGRX)vs › | $7.08M | 0.03 | 0.02 | 0.20 | 0.20 |
| Co-Diagnostics, Inc. (CODX)vs › | $7.07M | 0.14 | 0.05 | 0.03 | 0.02 |
| Longeveron Inc. (LGVN)vs › | $7.47M | 0.06 | 0.11 | 0.16 | 0.47 |
| Aclarion, Inc. (ACON)vs › | $6.73M | 0.00 | 0.00 | 0.00 | 0.00 |
| Enveric Biosciences, Inc. (ENVB)vs › | $6.67M | 0.00 | 0.00 | 0.00 | 0.00 |
| Ensysce Biosciences, Inc. (ENSC)vs › | $6.52M | N/A | 0.09 | 0.09 | 0.09 |
Debt/Equity
-0.11
Current Ratio
0.31
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2025-12-31 | -0.11 |
| 2025-09-30 | -0.11 |
| 2025-06-30 | 0.00 |
| 2025-03-31 | 0.00 |
| 2024-12-31 | 0.03 |
| 2024-09-30 | -0.01 |
| 2024-06-30 | -0.02 |
| 2024-03-31 | -0.01 |
| 2023-12-31 | -0.08 |
| 2023-09-30 | -0.43 |
| 2023-06-30 | -0.07 |
| 2023-03-31 | 0.04 |
| 2022-12-31 | 0.04 |
| 2022-09-30 | 0.02 |
| 2022-06-30 | 0.02 |
| 2022-03-31 | 0.02 |
| 2021-12-31 | 0.00 |
| 2021-09-30 | 0.00 |
| 2021-06-30 | 0.00 |
| 2021-03-31 | 0.00 |
| 2020-12-31 | 0.00 |
| 2020-09-30 | 0.00 |
| 2020-06-30 | 0.00 |
| 2020-03-31 | 0.00 |
